Interim Data Presented at SITC 2020
Investigational Intratumoral Cancer Immunotherapy
OncoSec’s VLA: Visceral Lesion Applicator
Clinical trial currently recruiting patients with TNBC
News & Events
- OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
Reclaiming Independence from Melanoma
“I was headed down a one-way street with a dead end.”
* Fran has since lost her battle with metastatic melanoma cancer. After two years of remission, her cancer returned. Fran requested to receive treatment again with TAVO, however, her cancer was advanced and difficult to treat. We at OncoSec honor her memory and continue to work to deliver safe and effective cancer treatments that can provide long-term benefits for patients.
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancers
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer
We have a track record of establishing, operating and evolving high-performance partnerships globally